8-K: Pyxis Oncology Announces Full Year 2024 Financial Results and Provides Business Update, Highlighting Positive Clinical Data and Strategic Focus

Pyxis Oncology reports positive preliminary data from its Phase 1 trial of micvotabart pelidotin (MICVO) in recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC), receives FDA Fast Track Designation, and streamlines operations to focus on MICVO clinical program.

Summary

• Pyxis Oncology reported its full year 2024 financial results and provided a business update on March 18, 2025.
• The company's lead therapeutic candidate, micvotabart pelidotin (MICVO), showed a confirmed 50% objective response rate in R/M HNSCC patients in a Phase 1 dose escalation trial.
• MICVO received Fast Track Designation from the FDA for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy.
• Pyxis Oncology initiated monotherapy expansion cohorts of MICVO for 2L and 3L R/M HNSCC patients with preliminary data expected in the second half of 2025 and the first half of 2026.
• A Phase 1/2 combination study of MICVO with Merck's KEYTRUDA in R/M HNSCC patients has been initiated, with preliminary data expected in the second half of 2025.
• The company has streamlined its organization, including a workforce reduction of approximately 20%, to focus resources on the MICVO clinical program.
• Pyxis Oncology's cash runway is expected to last into the second half of 2026.
• As of December 31, 2024, Pyxis Oncology had $128.4 million in cash and cash equivalents, including restricted cash, and short-term investments.
• Research and development expenses were $58.7 million for the year ended December 31, 2024, compared to $49.6 million for the year ended December 31, 2023.
• General and administrative expenses were $25.4 million for the year ended December 31, 2024, compared to $32.6 million for the year ended December 31, 2023.
• Net loss was $77.3 million, or ($1.32) per common share, for the year ended December 31, 2024, compared to $73.8 million, or ($1.85) per common share, for the year ended December 31, 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to promising clinical data, FDA Fast Track Designation, and a focused business strategy. However, a workforce reduction and net loss temper the overall sentiment.

Positives

• Positive preliminary data from the Phase 1 dose escalation trial of micvotabart pelidotin (MICVO) shows promise in treating R/M HNSCC.
• FDA Fast Track Designation for MICVO accelerates its development and review process.
• Initiation of monotherapy expansion cohorts and a combination study with Merck's KEYTRUDA expands the potential applications of MICVO.
• Streamlining the organization and focusing resources on MICVO improves efficiency and increases the likelihood of successful clinical program execution.
• The company's cash runway into the second half of 2026 provides financial stability for ongoing and planned clinical trials.
• The company has a deeply experienced team of oncology drug developers.
• The company has multiple clinical data catalysts in 2025.

Negatives

• A workforce reduction of approximately 20% may impact morale and productivity.
• Ken Kobayashi, M.D., F.A.C.P, is stepping down from his position as the Company's Chief Medical Officer.
• The company recorded a non-cash impairment loss of $21.0 million for in-process research and development (IPR&D) intangible asset related to PYX-107.
• Net loss was $77.3 million for the year ended December 31, 2024.

Risks

• The development of micvotabart pelidotin (MICVO) is subject to the inherent risks of drug research and development, including potential delays in or failure to obtain regulatory approvals.
• The company relies on third parties and collaborators to conduct clinical trials, manufacture product candidates, and develop and commercialize product candidates.
• The company faces competition from other drug candidates in the market.
• The company's projected cash runway may not be sufficient, and it may need additional funding.
• The company's ability to compete successfully against other drug candidates is not guaranteed.

Future Outlook

Pyxis Oncology expects its current cash, cash equivalents, and short-term investments will be sufficient to fund its operations into the second half of 2026.

Management Comments

• 'We are committed to the development of a novel therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma who will progress following platinum-based therapies and prior PD-(L)1 therapy, and those that progress after current and emerging EGFRi therapies,' said Lara S. Sullivan, M.D., President and Chief Executive Officer.
• 'Given the positive micvotabart pelidotin data, it is critical that we ensure the flawless execution of our clinical programs on the fastest possible timeline,' said Dr. Sullivan.
• 'I am confident that our focused approach will drive value for both patients and shareholders,' concluded Dr. Sullivan.

Industry Context

The focus on R/M HNSCC reflects a significant unmet need in oncology, as current treatments have limited long-term survival benefits. Pyxis Oncology's approach with MICVO, targeting the tumor microenvironment, represents a novel strategy compared to traditional cell-surface targeting ADCs. The collaboration with Merck to combine MICVO with KEYTRUDA aligns with the industry trend of exploring combination therapies to improve patient outcomes.

Comparison to Industry Standards

• The 50% objective response rate (ORR) observed with micvotabart pelidotin in R/M HNSCC patients is promising compared to the typical response rates seen with existing therapies in this heavily pretreated population.
• For example, single-agent EGFR inhibitors like cetuximab (Erbitux) have shown response rates in the range of 10-13% in similar patient populations.
• The Fast Track Designation from the FDA is a positive signal, indicating that the agency recognizes the potential of MICVO to address an unmet medical need.
• The company's focus on extracellular matrix (ECM) targeting with MICVO differentiates it from other ADC developers that primarily target cell surface antigens, such as Enhertu (trastuzumab deruxtecan) from Daiichi Sankyo and AstraZeneca, which targets HER2, or Trodelvy (sacituzumab govitecan) from Gilead, which targets Trop-2.
• The cash runway into 2H26 provides Pyxis Oncology with a competitive advantage, allowing it to focus on clinical development without immediate concerns about fundraising, compared to smaller biotech companies with shorter cash runways.

Management Changes

Stakeholder Impact

• Shareholders may experience increased value due to the positive clinical data and strategic focus.
• Employees may be affected by the workforce reduction of approximately 20%.
• Patients with R/M HNSCC may benefit from the development of a novel therapy.
• The company's suppliers and collaborators may be impacted by the portfolio prioritization and resource allocation.

Next Steps

• Continue Phase 1 Part 2 monotherapy expansion cohorts of MICVO for 2L and 3L R/M HNSCC patients.
• Advance Phase 1/2 combination study of MICVO and Merck's KEYTRUDA in patients with R/M HNSCC and other advanced solid tumors.
• Select a dose of micvotabart pelidotin in combination with pembrolizumab by mid-year 2025.
• Share preliminary data from the combination trial in the second half of 2025.
• Release preliminary data from patients who have received prior platinum and PD-1 inhibitor therapy in the second half of 2025.
• Release preliminary data from patients who have received prior EGFRi and PD-1 inhibitor therapy in the first half of 2026.

Key Dates